Drug Trial Radar · NCT00317330
A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis
Last checked: Nov 19, 2026Latest source record: Aug 27, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,400
Actual
Start
Dec 2004
Primary completion
Not stated
Study completion Jun 2005
Sponsor
- Sponsor type
- NIH
- First posted
- Apr 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the effectiveness of two different tuberculosis (TB) prevention strategies, DOTS or DOTS-A. DOTS is the current prevention strategy for TB. DOTS-A is an enhanced prevention strategy that will screen household members of individuals diagnosed with active TB and will provide enhanced treatment as needed. The study will be conducted in 8 communities located in Rio de Janeiro. Study participants will include 6400 males and females of all ages, including active TB patients and their household contacts. Patients with TB identified for treatment at the Health Clinics of 8 urban communities will be eligible. The communities will be assigned to 1 of the 2 prevention strategies, DOTS or DOTS-A. After 4 years, the information gathered during the study will be used to determine the incidence of TB in these communities to see which prevention strategy was more effective in decreasing TB.
Conditions
- Tuberculosis
Interventions
IsoniazidDrug
PyrazinamideDrug
RifampinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Municipal Health Department
Rio de Janeiro, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.